3 Healthcare Stocks Paying the Highest Dividends of 2025

The article evaluates three high-yielding healthcare stocks—Kenvue, Pfizer, and Omega Healthcare—advising investors to prioritize underlying business fundamentals over dividend yield alone. Kenvue, a Johnson & Johnson spin-off, is experiencing Q2 2025 sales declines and product-specific risks, leading to a 5.5% yield amid near-term uncertainty. Pfizer, with a 6.9% yield, is pursuing strategic acquisitions and government deals to counter a patent cliff, but its 90% payout ratio and past dividend cut raise concerns about dividend sustainability, positioning it as a turnaround story. Omega Healthcare, a senior-housing REIT yielding 6.6%, is presented as the most resilient, having maintained its dividend through the COVID-19 pandemic and now resuming growth, making it the comparatively least risky option.

Analysis

The article highlights the critical importance of evaluating underlying business fundamentals over dividend yield alone when considering high-yielding healthcare stocks. Kenvue, Pfizer, and Omega Healthcare are presented as examples, each with distinct risk-reward profiles. The general sentiment surrounding these opportunities is mixed and cautious, reflecting the nuanced assessment required by investors.

Kenvue, a spin-off from Johnson & Johnson, faces significant operational headwinds, including a 4% decline in Q2 2025 sales and a 4.2% organic sales drop, alongside a decrease in adjusted earnings to $0.29 per share. Its 5.5% dividend yield, substantially higher than the consumer staples average of 2.7%, reflects investor concerns exacerbated by product-specific risks related to Tylenol. This situation positions Kenvue as a contrarian play, requiring tolerance for near-term uncertainty in a newly independent entity.

Pfizer, yielding 6.9%, is actively addressing a patent cliff and industry headwinds through strategic initiatives, including the acquisition of Metsera and a deal with the U.S. government. However, its high payout ratio, hovering around 90%, and a history of dividend cuts (e.g., in 2009 post-Wyeth acquisition) introduce considerable risk to dividend sustainability. The stock's nearly 60% decline since late 2021 frames Pfizer as a turnaround story where the dividend's future is uncertain.

Omega Healthcare, a senior-housing focused REIT, offers an attractive 6.6% dividend yield and has demonstrated remarkable resilience by sustaining its dividend throughout the challenging COVID-19 pandemic. The company is now resuming growth, evidenced by over half a billion dollars in asset acquisitions in Q2 2025. This proven stability and renewed growth position Omega as the comparatively least risky option among the three for income-focused investors.

Key Decisions for Investors

• Investors should prioritize a thorough analysis of business fundamentals and risk factors over solely focusing on high dividend yields.
• For Kenvue, consider the near-term operational challenges and product-specific risks, weighing the high 5.5% yield against its limited dividend track record as a standalone entity.
• For Pfizer, assess the turnaround potential and strategic pipeline initiatives, but remain cautious regarding dividend sustainability given the 90% payout ratio and historical precedent of cuts.
• Omega Healthcare appears to be the most resilient option, offering a stable 6.6% yield and demonstrated ability to maintain dividends through severe industry downturns, making it suitable for income-focused investors seeking lower risk.